Tvardi Therapeutics Inc. has announced further updates from its Phase 2 REVERT IPF clinical trial evaluating TTI-101, an oral STAT3 inhibitor, in patients with idiopathic pulmonary fibrosis (IPF). Data from the study, which was previously announced as not meeting its primary endpoints in October 2025, include additional analyses on a subset of 40 patients who completed 12 weeks of treatment. The results show a 9.4% decrease from baseline in fibrosis score for patients treated with TTI-101, compared to a 2.4% decrease in the placebo group. Additionally, 63% of patients in the TTI-101 group experienced an increase in forced vital capacity $(FVC)$ at 12 weeks, versus 46% in the placebo group. The company has also stated that topline healthy volunteer data from a Phase 1 study of its next-generation STAT3 inhibitor, TTI-109, is expected in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622040) on January 08, 2026, and is solely responsible for the information contained therein.